Panbela Therapeutics is a clinical stage biopharmaceutical company developing therapeutics for the treatment of patients with cancer. Co.'s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition, a metabolic pathway of critical importance in multiple tumor types. The PBLA stock yearly return is shown above.
The yearly return on the PBLA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PBLA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|